NO20072983L - Anvendelse av paratyroidhormon for fremstilling av et medikament for a redusere risiko for frakturer - Google Patents

Anvendelse av paratyroidhormon for fremstilling av et medikament for a redusere risiko for frakturer

Info

Publication number
NO20072983L
NO20072983L NO20072983A NO20072983A NO20072983L NO 20072983 L NO20072983 L NO 20072983L NO 20072983 A NO20072983 A NO 20072983A NO 20072983 A NO20072983 A NO 20072983A NO 20072983 L NO20072983 L NO 20072983L
Authority
NO
Norway
Prior art keywords
reduce
risk
manufacture
parathyroid hormone
drug
Prior art date
Application number
NO20072983A
Other languages
English (en)
Inventor
Janet Mary Hock
Gregory A Gaich
Willard H Dere
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26792729&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20072983(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of NO20072983L publication Critical patent/NO20072983L/no
Application filed by Lilly Co Eli filed Critical Lilly Co Eli

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Steroid Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)

Abstract

Oppfinnelsen angår anvendelse av paratyroidhormon for fremstilling av et medikament for å redusere risiko for flukturer. Medikamentet oppnådd ved anvendelse av oppflnnelsen kan anvendes for å øke hardheten eller stivheten til ben ved et sete med et potensielt eller virkelig traume, slik som hoften eller ryggraden til en person med risiko for eller som lider av osteoporose. Anvendelsen ifølge oppflnnelsen kan redusere sannsynligheten for vertebralfluktur, redusere tilfellet av multiple vertebrale fluktur, redusere alvorligheten av vertebra! fliaktur og/eller redusere forekomst av ikke-vertebral fraktur.
NO20072983A 1998-08-19 2007-06-11 Anvendelse av paratyroidhormon for fremstilling av et medikament for a redusere risiko for frakturer NO20072983L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9715198P 1998-08-19 1998-08-19
US9974698P 1998-09-10 1998-09-10
PCT/US1999/018961 WO2000010596A1 (en) 1998-08-19 1999-08-19 Method of increasing bone toughness and stiffness and reducing fractures

Publications (1)

Publication Number Publication Date
NO20072983L true NO20072983L (no) 2000-11-24

Family

ID=26792729

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20005947A NO323984B1 (no) 1998-08-19 2000-11-24 Anvendelse av paratyroidhormon for fremstilling av et preparat for a redusere benfraktur
NO20072983A NO20072983L (no) 1998-08-19 2007-06-11 Anvendelse av paratyroidhormon for fremstilling av et medikament for a redusere risiko for frakturer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20005947A NO323984B1 (no) 1998-08-19 2000-11-24 Anvendelse av paratyroidhormon for fremstilling av et preparat for a redusere benfraktur

Country Status (32)

Country Link
US (2) US6977077B1 (no)
EP (3) EP2266598B1 (no)
JP (5) JP2002523375A (no)
KR (1) KR100454207B1 (no)
CN (1) CN1205997C (no)
AR (1) AR033639A1 (no)
AT (1) ATE231000T1 (no)
AU (1) AU746277B2 (no)
BR (1) BR9909445A (no)
CA (1) CA2325371C (no)
CO (1) CO5130020A1 (no)
CY (2) CY1113343T1 (no)
CZ (1) CZ301017B6 (no)
DE (2) DE15152726T1 (no)
DK (4) DK2266598T3 (no)
DZ (1) DZ2873A1 (no)
EA (1) EA003362B1 (no)
ES (4) ES2393200T3 (no)
HR (1) HRP20000755A2 (no)
HU (2) HU230697B1 (no)
ID (1) ID29039A (no)
IL (2) IL138829A0 (no)
MY (1) MY129227A (no)
NO (2) NO323984B1 (no)
NZ (1) NZ507056A (no)
PE (1) PE20001089A1 (no)
PL (1) PL201688B1 (no)
PT (4) PT2907522T (no)
TR (1) TR200003455T2 (no)
TW (1) TW576747B (no)
UA (1) UA72205C2 (no)
WO (1) WO2000010596A1 (no)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770623B1 (en) * 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
DZ2873A1 (fr) * 1998-08-19 2003-12-15 Lilly Co Eli Procédé pour augmenter la dureté et la rigidité osseuse.
US20040033950A1 (en) 2000-09-26 2004-02-19 Hock Janet M. Method of increasing bone toughness and stiffness and reducing fractures
WO2001022093A1 (en) * 1999-09-20 2001-03-29 Eli Lilly And Company Method for monitoring treatment with a parathyroid hormone
US7247609B2 (en) 2001-12-18 2007-07-24 Universitat Zurich Growth factor modified protein matrices for tissue engineering
EP1531855A4 (en) * 2002-01-10 2009-07-22 Osteotrophin Llc TREATMENT OF BONE DISEASES WITH SKELETTAL ANABOLIKA
US8088734B2 (en) 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
KR20060058133A (ko) * 2003-09-19 2006-05-29 화이자 프로덕츠 인코포레이티드 2-알킬리덴-19-노르-비타민 ｄ 유도체 및 부갑상선호르몬의 조합을 포함하는 약학 조성물 및 방법
US20060189533A1 (en) * 2004-05-10 2006-08-24 Nastech Pharmaceutical Company Inc. Stable pharmaceutical dosage forms of teriparatide
CA2567056A1 (en) * 2004-05-10 2005-12-08 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of parathyroid hormone
US20060052305A1 (en) * 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. Method of treating osteoporosis using intranasal parathyroid hormone
US20060127320A1 (en) * 2004-05-10 2006-06-15 Nastech Pharmaceutical Company Inc. Method of delivering parathyroid hormone to a human
US7556821B2 (en) 2004-05-13 2009-07-07 Alza Corporation Apparatus and method for transdermal delivery of parathyroid hormone agents
US7648965B2 (en) 2004-05-14 2010-01-19 Unigene Laboratories Inc. Method for fostering bone formation and preservation
US20060069021A1 (en) * 2004-08-13 2006-03-30 Nastech Pharmaceutical Company Inc. Compositions and methods for intranasal administration of inactive analogs of PTH or inactivated preparations of PTH or PTH analogs
WO2006073711A2 (en) 2005-01-06 2006-07-13 Kuros Biosurgery Ag Use of a matrix comprising a contrast agent in soft tissues
US8575101B2 (en) 2005-01-06 2013-11-05 Kuros Biosurgery Ag Supplemented matrices for the repair of bone fractures
EP1879608A4 (en) * 2005-05-11 2009-11-11 Unigene Lab Inc METHOD FOR STIMULATING BONE FORMATION AND PRESERVATION
US20070173447A1 (en) * 2005-10-25 2007-07-26 Nastech Pharmaceutical Company Inc. Method for treating osteoporosis by intranasal delivery of teriparatide with an anti-resorptive agent
CA2628945A1 (en) * 2005-11-10 2007-05-24 Board Of Control Of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US20080051332A1 (en) * 2005-11-18 2008-02-28 Nastech Pharmaceutical Company Inc. Method of modulating hematopoietic stem cells and treating hematologic diseases using intranasal parathyroid hormone
US20080119408A1 (en) * 2006-07-07 2008-05-22 Nastech Pharmaceutical Company Inc. Pth formulations for intranasal delivery
EP1961765A1 (en) * 2006-12-08 2008-08-27 Zealand Pharma A/S Truncated PTH peptides with a cyclic conformation
DK2136850T3 (da) 2007-04-13 2012-04-10 Kuros Biosurgery Ag Polymervævforsegling
US20110137243A1 (en) * 2007-09-06 2011-06-09 Abbott Cardiovascular Systems Inc. Coating On A Balloon Device
US9457056B2 (en) * 2007-12-04 2016-10-04 Ben-Gurion University Of The Negev Research And Development Authority Peptides comprising alternating hydrophobic and anionic amino acids for treatment of osteoporosis
WO2009083544A2 (en) 2007-12-28 2009-07-09 Kuros Biosurgery Ag Pdgf fusion proteins incorporated into fibrin foams
KR20190095552A (ko) * 2009-09-09 2019-08-14 아사히 가세이 파마 가부시키가이샤 1회당 100∼200 단위의 ｐｔｈ가 주 1회 투여되는 것을 특징으로 하는, ｐｔｈ 함유 골다공증 치료/예방제
BR112012013725A2 (pt) 2009-12-07 2017-01-10 Univ Michigan Tech paratormônio de urso preto e métodos de usar o paratormônio de uso preto.
US9295663B2 (en) 2010-07-14 2016-03-29 Abbott Cardiovascular Systems Inc. Drug coated balloon with in-situ formed drug containing microspheres
WO2012111852A1 (ja) * 2011-02-17 2012-08-23 帝人ファーマ株式会社 椎体骨折治療剤及びその評価方法
EP2686027B1 (en) 2011-03-16 2021-05-05 Kuros Biosurgery AG Pharmaceutical formulation for use in spinal fusion
KR20150116467A (ko) 2011-06-07 2015-10-15 아사히 가세이 파마 가부시키가이샤 고순도 ｐｔｈ 함유 동결 건조 제제 및 그의 제조 방법
US9700485B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US11492386B2 (en) 2016-02-01 2022-11-08 Eli Lilly And Company Parathyroid hormone-anti-RANKL antibody fusion compounds
US20190381341A1 (en) * 2017-02-01 2019-12-19 The Johns Hopkins University Parathyroid hormone and regeneration of degenerative discs disease
US20200289621A1 (en) * 2017-09-22 2020-09-17 Asahi Kasei Pharma Corporation Teriparatide-containing liquid pharmaceutical composition having excellent stability
ES3009869T3 (en) 2018-10-29 2025-03-31 Asahi Kasei Pharma Corp An improved teriparatide dosage regimen for use in preventing or treating osteoporosis characterized by administering teriparatide or salt thereof twice a week
EP4010360A1 (en) 2019-08-09 2022-06-15 Flagship Pioneering Innovations VI, LLC Modulators of parathyroid hormone receptor (pthr1)
GB2590692A (en) * 2019-12-24 2021-07-07 Corthotec Ltd Composition for improved bone fracture healing

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
IL78342A (en) 1985-04-04 1991-06-10 Gen Hospital Corp Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
DE3935738A1 (de) 1989-10-27 1991-05-08 Forssmann Wolf Georg Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff
US5208041A (en) 1991-05-23 1993-05-04 Allelix Biopharmaceuticals Inc. Essentially pure human parathyroid hormone
US5556940A (en) 1994-06-20 1996-09-17 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
JPH0873376A (ja) * 1994-09-07 1996-03-19 Asahi Chem Ind Co Ltd 骨粗鬆症治療薬
JPH10511095A (ja) * 1994-12-19 1998-10-27 ベス イスラエル ディーコネス メディカル センター インコーポレイテッド 副甲状腺ホルモン又はその作動薬の低用量継続投与
US5747456A (en) * 1994-12-19 1998-05-05 Beth Israel Deaconess Medical Center Continuous low-dose administration of parathyroid hormone or its agonist
EP1283035A3 (en) * 1994-12-22 2003-03-19 AstraZeneca AB Therapeutic preparation for inhalation containing parathyroid hormone
JPH08310965A (ja) * 1995-05-16 1996-11-26 Chugai Pharmaceut Co Ltd 骨癒合促進剤
HRP20000109A2 (en) * 1997-09-09 2001-02-28 Hoffmann La Roche FRACTURE HEALING USING PTHrP ANALOGS
ZA9811127B (en) 1997-12-09 2000-07-11 Lilly Co Eli Stabilized teriparatide solutions.
DZ2873A1 (fr) * 1998-08-19 2003-12-15 Lilly Co Eli Procédé pour augmenter la dureté et la rigidité osseuse.
US20040033950A1 (en) 2000-09-26 2004-02-19 Hock Janet M. Method of increasing bone toughness and stiffness and reducing fractures
US6907597B1 (en) 2000-10-13 2005-06-14 Ati International Srl Method and apparatus for constructing an executable program in memory
US6967759B2 (en) 2001-12-31 2005-11-22 Texas Instruments Incorporated Pulse width modulation sequence generation
JP5796714B2 (ja) 2012-01-13 2015-10-21 株式会社リコー 定着装置及び画像形成装置
EP2949301B1 (en) 2014-05-27 2018-04-18 The Procter and Gamble Company Absorbent core with curved and straight absorbent material areas

Also Published As

Publication number Publication date
CZ20004134A3 (cs) 2001-08-15
ES2190244T3 (es) 2003-07-16
EA003362B1 (ru) 2003-04-24
DE69904918D1 (de) 2003-02-20
ES2549551T3 (es) 2017-11-27
EP1059933B1 (en) 2003-01-15
EP2907522A1 (en) 2015-08-19
HU1200430D0 (hu) 2001-11-28
JP2011021035A (ja) 2011-02-03
HRP20000755A2 (en) 2001-02-28
DK2266598T3 (en) 2017-05-15
EP1059933A1 (en) 2000-12-20
UA72205C2 (uk) 2005-02-15
EA200001015A1 (ru) 2001-02-26
US20050197294A1 (en) 2005-09-08
TW576747B (en) 2004-02-21
JP2017190332A (ja) 2017-10-19
US7163684B2 (en) 2007-01-16
HU230697B1 (hu) 2017-09-28
DE15152726T1 (de) 2015-12-10
CA2325371C (en) 2004-08-17
PT1059933E (pt) 2003-06-30
EP2266598B1 (en) 2017-02-22
EP2266598A1 (en) 2010-12-29
TR200003455T2 (tr) 2001-06-21
PL343595A1 (en) 2001-08-27
DE69904918T2 (de) 2003-11-13
HK1102496A1 (en) 2007-11-23
CN1205997C (zh) 2005-06-15
DK2907522T1 (da) 2015-10-19
DK2907522T3 (en) 2017-10-23
KR20010072763A (ko) 2001-07-31
JP6177718B2 (ja) 2017-08-09
CN1308545A (zh) 2001-08-15
MY129227A (en) 2007-03-30
HUP0101594A3 (en) 2002-01-28
AR033639A1 (es) 2004-01-07
DZ2873A1 (fr) 2003-12-15
CA2325371A1 (en) 2000-03-02
PT2907522T (pt) 2017-10-23
JP2015028065A (ja) 2015-02-12
ID29039A (id) 2001-07-26
PL201688B1 (pl) 2009-04-30
DK1769804T3 (da) 2012-10-15
US6977077B1 (en) 2005-12-20
HUP0101594A2 (hu) 2001-11-28
PT2266598T (pt) 2017-05-02
JP2014139220A (ja) 2014-07-31
IL138829A (en) 2011-01-31
WO2000010596A1 (en) 2000-03-02
AU746277B2 (en) 2002-04-18
JP2002523375A (ja) 2002-07-30
HK1212602A1 (en) 2016-06-17
NZ507056A (en) 2003-10-31
EP2907522B1 (en) 2017-08-02
ES2393200T3 (es) 2012-12-19
PE20001089A1 (es) 2000-11-04
PT1769804E (pt) 2012-11-13
KR100454207B1 (ko) 2004-10-26
NO20005947D0 (no) 2000-11-24
ES2621653T3 (es) 2017-07-04
NO20005947L (no) 2000-11-24
DK1059933T3 (da) 2003-04-07
CY1119552T1 (el) 2018-03-07
NO323984B1 (no) 2007-07-30
ATE231000T1 (de) 2003-02-15
IL138829A0 (en) 2001-10-31
AU5575099A (en) 2000-03-14
CY1113343T1 (el) 2016-06-22
CO5130020A1 (es) 2002-02-27
CZ301017B6 (cs) 2009-10-14
ES2549551T1 (es) 2015-10-29
BR9909445A (pt) 2000-12-12
HK1030545A1 (en) 2001-05-11

Similar Documents

Publication Publication Date Title
NO20072983L (no) Anvendelse av paratyroidhormon for fremstilling av et medikament for a redusere risiko for frakturer
Schildhauer et al. Triangular osteosynthesis of vertically unstable sacrum fractures: a new concept allowing early weight-bearing
Mattsson et al. Resorbable cement for the augmentation of internally-fixed unstable trochanteric fractures: a prospective, randomised multicentre study
Kaplan et al. Surgical management of hip fractures: an evidence-based review of the literature. II: intertrochanteric fractures
Laohapoonrungsee et al. Two-hole side-plate DHS in the treatment of intertrochanteric fracture: results and complications
Harrington Technical details in relation to the successful use of instrumentation in scoliosis
Birknes et al. Adult degenerative scoliosis: a review
Boachie-Adjei et al. Transpedicular lumbar wedge resection osteotomy for fixed sagittal imbalance: surgical technique and early results
Kasten et al. Long-term results of iliac wing fixation below extensive fusions in ambulatory adult patients with spinal disorders
Grant et al. Internal fixation of osteoporotic bone
Paspati et al. Hip fracture epidemiology in Greece during 1977–1992
Passias et al. Three-column osteotomy in adult spinal deformity: an analysis of temporal trends in usage and outcomes
Miyakoshi et al. Improvement of spinal alignment and quality of life after corrective surgery for spinal kyphosis in patients with osteoporosis: a comparative study with non-operated patients
DeRogatis et al. Management of subtrochanteric femoral fracture nonunions
Suckel et al. Evaluation of complications of three different types of proximal extra-articular femur fractures: differences in complications, age, sex and surviving rates
Rozell et al. Recent advances in the treatment of hip fractures in the elderly
Magu et al. Modified Pauwels' intertrochanteric osteotomy in neglected femoral neck fractures in children: a report of 10 cases followed for a minimum of 5 years
Sardi et al. Use of supplemental rod constructs in adult spinal deformity surgery: a review
Schildhauer et al. Multisegmental open sacral fracture due to impalement: a case report
Parikh et al. Rate of bone mineral density testing and subsequent fracture-free interval after distal forearm fracture in the Medicare population
Neviaser et al. Is kyphoplasty the standard of care for compression fractures in the spine, especially in the elderly?
Koong et al. Management of lower limb fractures in patients with spinal cord injuries
Sasagawa et al. Traumatic spondyloptosis at the thoracolumbar junction in a patient with diffuse idiopathic skeletal hyperostosis: a case report
Roux Antifracture efficacy of strontium ranelate in postmenopausal osteoporosis
EP1295605A3 (en) Method of increasing bone toughness and stiffness and reducing fractures

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application